Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.30 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277249 | 0.90 | F10 (0.36) | HSD17B1F10PELI1HSD17B10 | |
| SCHEMBL1277164 | 0.88 | BACE1 (0.38) | HSD17B1F10PELI1HSD17B10 | |
| SCHEMBL12709241 | 0.87 | BAZ2B (0.34) | HSD17B1F10PELI1SMN1; SMN2 | |
| SCHEMBL1277438 | 0.87 | SLC9A3 (0.40) | HSD17B1F10SLC9A1SLC9A3PELI1 | |
| SCHEMBL1277392 | 0.86 | HSD17B1 (0.36) | HSD17B1F10SLC9A1SLC9A3PELI1 | |
| SCHEMBL1277366 | 0.86 | HSD17B1 (0.33) | HSD17B1F10PELI1HSD17B10 | |
| SCHEMBL1277316 | 0.85 | MGAM (0.39) | HTTHSD17B10 | |
| SCHEMBL1277443 | 0.84 | HSD17B1 (0.33) | HSD17B1MTORSLC9A1SLC9A3 | |
| SCHEMBL1277265 | 0.83 | DHODH (0.39) | HSD17B1F10PELI1 | |
| SCHEMBL1277277 | 0.82 | BACE1 (0.40) | HSD17B1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | HSD17B1 2621/4885F10 4727/4885MTOR 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.